We are currently developing a platform technology device for clinical applications in core tissue biopsy. Our BioScoop™ Biopsy System with integrated BxSeal™ technology for hemostasis, represents a new approach to percutaneous needle biopsy. The System will  enable physicians to achieve safer and definitive tissue capture using advanced needle-tissue characterisation and automated control.

Key Features of Invention:

  1. Increasing Procedural Functionality:
    • BioScoop™ technology invented for reduced physician effort and skill
    • Automatic tissue capture mechanism for ease of use
  2. Enhancing Procedural Safety:
    • Exclusive BxSeal™ system, minimizing hemorrhaging for Patient Safety
    • Automated, contamination-free sample handling for Procedural Safety
  3. Improving Accuracy of Diagnosis:
    • Pre-calibrated mechanism for counteracting variation in tissue types
    • Clean distal-end cutting action prevents sample fragmentation
    • Automated tissue capture ensures consistent samples
  4. Enabling Cost-effective Diagnosis:
    • Affordable results for both patients and healthcare providers


The invention comprises a method that significantly improves on the technique of aspiration needle biopsy as well as a device that automates the entire biopsy procedure while improving the tissue sample size.
read more
  • Novel dual-function needle tip design with 3 distinct cutting edges
  • Integrated piercing and cutting in a single insertion
  • New electro-mechanical device configuration for on-demand soft-tissue resection
  • Organ- and disease-specific tissue characterization
  • Control logic automation for physician-selectable method of biopsy
  • Automated (touch-less) tissue resection, transfer and storage
  • Platform technology scalable to other soft-tissue organ biopsy

A safety feature of the invention of the biopsy device to assist in concurrently delivering a hemostatic agent inside the biopsy track to significantly reduce the risk of internal hemorrhage.
read more
  • Concurrent infusion of hemostatic agents
  • Selectable volume and initiation of delivery
  • Choice of agent based on organ tissue condition
  • Optional continuous volume infusion
  • Provision for simultaneous infusion of multiple or multi-component agents
  • Short procedural time: 3-5 sec. including hemostasis